Skip to Late-Breaking Abstracts »
All accepted abstracts are available in the Journal for ImmunoTherapy of Cancer (JITC).
Abstract Titles
Poster Presentation Dates
All odd numbered posters will be presented on Wednesday, Nov. 11, from 5:15-5:45 p.m. EST and Friday, Nov. 13, from 4:40-5:10 p.m. EST. Even numbered posters will be presented on Thursday, Nov. 12, from 4:50-5:20 p.m. EST and Saturday, Nov. 14, from 1-1:30 p.m. EST.
Posters will be on display from 8 a.m. on Monday, Nov. 9, until the virtual poster hall closes on December 31, 2020.
| # | Type | Title | Authors | Category | Keywords |
|---|---|---|---|---|---|
| 550 | Poster Presentation | An Axl-targeting monoclonal antibody that inhibits Axl activity and potently stimulates the innate immune response | Diego Alvarado; Laura Vitale, BS; Mike Murphy; Thomas O'Neill, BA; Edward J. Natoli; Jay Lillquist; Linda Crew; Anna Wasiuk; Jeffrey Weidlick, BS; Crystal Sisson; Jenifer Widger, BA; Laura Mills-Chen; Andrea Crocker, BS; Colleen Patterson; James M. Boyer; Eric Forsberg; April R. Baronas; Taylor M. Mathieu; Amelia C. Fields; Russell Hammond; Li-Zhen He, MD; Joel Goldstein, PhD; Lawrence J. Thomas, PhD; Henry C. March; Tibor Keler, PhD; | Immune-stimulants and immune modulators | Antibody; Bispecifics; Checkpoint blockade; Coinhibition; Dendritic cell; Immune suppression; Monocyte/Macrophage; Myeloid cells; Targeted therapy; Tumor microenvironment |
| 552 | Poster Presentation | SUMOylation inhibitor TAK-981 activates NK cells and macrophages via Type I interferon signaling and shows synergistic activity in combination with rituximab and daratumumab in preclinical models | Akito Nakamura, PharmD; Keli Song, PhD; Stephen Grossman, PhD; Kristina Xega; Yuhong Zhang; Allison J. Berger, PhD; Allison J. Berger, PhD; Gary S. Shapiro, PhD; Dennis Huszar, PhD; | Immune-stimulants and immune modulators | Antibody; Leukemia/Lymphoma; Monocyte/Macrophage; NK/NK T cell; Post-translational modifications |
| 553 | Poster Presentation | CUE-100 series Immuno-STATs from concept to the clinic: Leveraging protein engineering to stimulate and selectively deliver affinity-attenuated IL-2 to antigen-specific T cells | Alex Histed, MSc; Natasha Girgis, PhD; Miguel Moreta; Jonathan Soriano, MSc; Luke Witt, B.S.; Zohra Merazga, MSc; Fulvio Diaz; Fan Zhao, PhD; Melissa Kemp, PhD; Paige Ruthardt, MSc; Dharma Thapa, PhD; Anish Suri, PhD; Ronald D. Seidel, PhD; Kenneth J. Pienta, MD; Mary C. Simcox, PhD; Steven N. Quayle, PhD; John F. Ross, Ph.D.; Saso Cemerski, PhD; Saso Cemerski, PhD; Saso Cemerski, PhD; | Immune-stimulants and immune modulators | Antigen presenting cells; Clinical trial; Cytokine; T cell; Tumor infiltrating lymphocytes (TILs); Vaccine |
| 555 | Poster Presentation | Inhibition of FOXP3 by stapled alpha-helical peptides alters Regulatory T Cell function | Katrina M. Hawley, AB; Rachel J. Eclov, PhD; Marie Fefferman, MD; Gregory H. Bird, PhD; Mathew R. Schnorenberg; Ravand Samaeekia, MD; Loren D. Walensky, MD, PhD; Matthew V. Tirrell, PhD; James L. LaBelle, MD, PhD; | Immune-stimulants and immune modulators | Regulatory T cell (Treg cell); Targeted therapy |
| 557 | Poster Presentation | Determining the efficacy of ADCC by the 3D-EX ex vivo platform utilizing tumoroids of fresh patient tumor samples with intact tumor microenvironment | Jenny Kreahling, PhD; Jared C. Ehrhart, PhD; Stephen Iwanowycz, PhD; Mibel Pabon, PhD; Tina Pastoor; Soner Altiok, MD, PhD; | Immune-stimulants and immune modulators | Antibody; Checkpoint blockade; Cytokine; Gene expression; Immune monitoring; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 558 | Poster Presentation | Programmed death (PD)-1 and PD-ligand-1 inhibitors in the treatment of non-small cell lung cancer: a systematic review of their efficacy and safety | Melissa Lingohr-Smith; Chelsea Deitelzweig; Grace Lin; Jay Lin; | Immune-stimulants and immune modulators | Checkpoint blockade; Clinical trial; Targeted therapy |
| 559 | Poster Presentation | Fostriecin potentiates genome instability and anti-tumor immunity in ovarian cancer | Remya Raja, PhD; Christopher Wu; Kristina A. Butler, M.D., MS; Marion Curtis, Ph.D.; | Immune-stimulants and immune modulators | Chemotherapy; Cytokine; Inflammation; Solid tumors; T cell |
| 560 | Poster Presentation | Alpha-tocopheryloxyacetic acid induces apoptosis of murine rhabdomyosarcoma in vitro while modulating innate and adaptive immune responses in vivo | Fernanda Szewc, MSc; Longzhen Song, Ph.D.; Sean P. Rinella, MPH, CCRP; Christopher Dubay, Ph.D.; Emmanuel T. Akporiaye, Ph.D.; William L. Redmond, Ph.D.; Christian M. Capitini, MD; | Immune-stimulants and immune modulators | Gene expression; Immune suppression; Myeloid cells; Pediatric tumors; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Epigenetics; RNA |
| 561 | Poster Presentation | DuoBody®-PD-L1×4-1BB (GEN1046) induces superior immune-cell activation, cytokine production and cytotoxicity by combining PD-L1 blockade with conditional 4-1BB co-stimulation | Alexander Muik, PhD; Isil Altintas, PhD; Friederike Gieseke; Rachelle Kosoff, PhD; Kristina Schödel; Theodora Salcedo; Saskia Burm, PhD; Aras Toker; Lena M. Kranz, PhD; Mathias Vormehr; David Eisel; Mark Fereshteh, PhD; Özlem Türeci; Esther Breij, PhD; Tahamtan Ahmadi; Ugur Sahin, MD; Maria Jure-Kunkel; | Immune-stimulants and immune modulators | Antibody; Bispecifics; Checkpoint blockade; Coinhibition; Costimulation; Targeted therapy |
| 562 | Poster Presentation | SO-C101 induces NK cell cytotoxicity and potentiates antibody-dependent cell cytotoxicity and anti-tumor activity | Zuzana Antosova, PhD; Nada Podzimkova, MSc; Marketa Jiratova, MSc; Eva Nedvedova, PhD; Guy de Martynoff, PhD, CMO; David Bechard, PhD, CEO; Ulrich Moebius, PhD,CSO; Radek Spisek, MD,PhD,CEO; Irena Adkins, PhD; | Immune-stimulants and immune modulators | Antibody; Cytokine; Immune adjuvant; Leukemia/Lymphoma; Solid tumors; T cell |
| 563 | Poster Presentation | Pharmacodynamics and pharmacokinetics of SO-C101 in cynomolgus monkeys | Nada Podzimkova, MSc; Irena Adkins, PhD; Irena Adkins, PhD; Guy de Martynoff, PhD, CMO; David Bechard, PhD, CEO; Radek Spisek, MD,PhD,CEO; Ulrich Moebius, PhD,CSO; | Immune-stimulants and immune modulators | Cytokine; Immune adjuvant; NK/NK T cell; Regulatory T cell (Treg cell); T cell |
| 564 | Poster Presentation | Potency-reduced and extended half-life IL12 heterodimeric Fc-fusions exhibit strong anti-tumor activity with potentially improved therapeutic index compared to native IL12 agents | Matthew J. Bernett, PhD; Rajat Varma, PhD; Ke Liu, PhD; Christine Bonzon, PhD; Rumana Rashid, PhD; Nicole Rodriguez, PhD; Nargess Hassanzadeh-Kiabi, PhD; Connie Ardila; Seung Chu, PhD; Umesh Muchhal, PhD; John R. Desjarlais, PhD; | Immune-stimulants and immune modulators | Bispecifics; Cytokine; Solid tumors; Tumor microenvironment |
| 565 | Poster Presentation | A novel long-acting interleukin-7 agonist, NT-I7, increases cytotoxic CD8+ T cells and enhances survival in mouse glioma models | Subhajit Ghosh, PhD; Ran Yan, PhD; Sukrutha Thotala; Arijita Jash, PhD; Anita Mahadevan, BS; Tong Hu, BS; Byung H. Lee, PhD; Se Hwan Yang, PhD; Dennis Hallahan, MD, PhD; Milan Chheda, MD; Dinesh Thotala, PhD; Jian L. Campian, MD, PhD; Jian L. Campian, MD, PhD; | Immune-stimulants and immune modulators | Cytokine; Radiotherapy; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 566 | Poster Presentation | MDK-202: An empirically-designed peptidyl agonist of the IL-2/15βγc receptor, devoid of Rα interaction, unrelated to IL-2 or IL-15, and fused to an Fc-domain for PK enhancement | William J. Dower, PhD; Steven E. Cwirla; Blake M. Williams, MS; Praechompoo Pongtornpipat, MS; Prarthana Joshi, ME; Sandra M. Wang, BSc; Alice V. Bakker, BA; Michael C. Needels, PhD; Ronald W. Barrett, PhD; | Immune-stimulants and immune modulators | Cytokine; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 567 | Poster Presentation | MDK1319/MDK-701: A potent fully efficacious peptidyl agonist of IL-7Rαγc, designed with no reference to cytokine or receptor structure and unrelated to IL-7, fused to an Fc-domain for PK enhancement | William J. Dower, PhD; Alice V. Bakker, BA; Steven E. Cwirla; Prarthana Joshi, ME; Praechompoo Pongtornpipat, MS; Blake M. Williams, MS; Sandra M. Wang, BSc; Michael C. Needels, PhD; Ronald W. Barrett, PhD; | Immune-stimulants and immune modulators | COVID and Immunotherapy; CAR T cells; Cytokine; Immune adjuvant; T cell; T cell lineages; Vaccine |
| 568 | Poster Presentation | XTX201, a protein-engineered IL-2, exhibits tumor-selective activity in mice without peripheral toxicities in non-human primates | Minjie Zhang; Wilson Guzman; Parker Johnson; Megan McLaughlin; Kurt Jenkins, PhD; Hsin-Jung Wu; Hanumantha Rao Madala; Caitlin O'Toole; Magali Pederzoli-Ribeil; Raphael Rozenfeld; Huawei Qiu; Margaret L. Karow, PhD; Tim Clackson; Ronan O'Hagan; Jennifer O'Neil; Ugur Eskiocak, PhD; | Immune-stimulants and immune modulators | Cytokine |
| 569 | Poster Presentation | Targeting IL-15 delivery to PD-L1 Expressing Tumors with an Anti-PD-L1-IL-15 Cytokine Fusion IgM to Enhance T Cell and NK Cell Mediated Tumor Cytotoxicity | Angus M. Sinclair, PhD; Thierry D. Giffon; Dean Ng, Ph.D.; Poonam Yakkundi, Ph.D.; Hope Lancero, Ph.D.; Marigold Manlusoc; Rodnie Rosete; Avneesh Saini, Ph.D.; Madeline Tran; Kevin Carlin, Ph.D.; Chitra Saraiya; Ramesh Baliga, Ph.D.; Bruce Keyt, Ph.D.; | Immune-stimulants and immune modulators | Antibody; Bispecifics; Checkpoint blockade; Cytokine; NK/NK T cell; T cell; Tumor infiltrating lymphocytes (TILs) |
| 570 | Poster Presentation | IL-15/IL-15Rα heterodimeric complex as cancer immunotherapy in murine breast cancer models | Siqi Guo; Ronald Smeltz B. Smeltz, PhD; Anthony Nanajian; Richard Heller; Siqi Guo; | Immune-stimulants and immune modulators | Cytokine; Solid tumors; T cell |
| 571 | Poster Presentation | ANV419 is a novel CD122-selective IL-2/anti-IL-2 antibody fusion protein with potent CD8 T cell and NK cell stimulatory function in vitro and in vivo | Christoph Huber, PhD; Andreas Katopodis, PhD; Barbara Branetti; Jean-Michel Rondeau; Simone Popp; Catherine Regnier; Daniel Kaiser; | Immune-stimulants and immune modulators | Antibody; Cytokine; Immune adjuvant; Immune toxicity; NK/NK T cell; Regulatory T cell (Treg cell); T cell |
| 572 | Poster Presentation | Fibroblast activating protein (FAP)-targeting IL-12 (anti-FAP/IL-12) TMEkine™ potentiates anti-cancer effects in preclinical cancer models | Donggeon Kim, DVM,PhD; Donggeon Kim, DVM,PhD; Dahea Lee; Soomin Ryu; Yeongseon Byeon, PhD; Kyoung-Ho Pyo, PhD; Jae-Hwan Kim, PhD; Seul Lee; Dong Kwon Kim; Eun Ji Lee; Seung Yeon Oh; Byoung Chul c. Cho, MD, PhD; | Immune-stimulants and immune modulators | Antibody; Bispecifics; Cytokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 573 | Poster Presentation | A novel human anti-PD1/IL15 bi-functional protein with robust anti-tumor activity and low systemic toxicity | Dan Lu, MS; Zhanna Polonskaya; Tzu-Pei Chang, PhD; Stella Martomo, PhD; Xenia Luna; zhikai zhang; Stanley Ng; Faical Miyara, PhD; Jeegar Patel; | Immune-stimulants and immune modulators | Antibody; Bispecifics; Checkpoint blockade; Cytokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| 574 | Poster Presentation | ONM-400, a Novel Approach for Interleukin-2 Therapy Using a pH-Activated Nanoparticle Targeting Metabolic Acidosis in Solid Cancers | Xinliang Ding, PhD; Jason B. Miller, PhD; Qingtai Su, PhD; Qingtai Su, PhD; Stephen Gutowski; Ashley Campbell; Drew Robinson; Tian Zhao, PhD; | Immune-stimulants and immune modulators | Cytokine; Solid tumors; Targeted therapy; Tumor microenvironment |
| 575 | Poster Presentation | Regression by hetIL-15 monotherapy in different mouse breast cancer models correlates with intratumoral infiltration of a novel population of dendritic cells | Sevasti Karaliota; Dimitris Stellas; Vasiliki Stravokefalou, MSc.; Bethany Nagy, BS; Cristina Bergamaschi, PhD; Barbara K. Felber, PhD; George N. Pavlakis, M.D., Ph.D.; | Immune-stimulants and immune modulators | Antigen presenting cells; Cytokine; Dendritic cell; Immune monitoring; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 576 | Poster Presentation | NL-201, a de novo IL-2 and IL-15 agonist, demonstrates enhanced in vivo antitumor activity in combination with multiple cancer immunotherapies | Carl Walkey, PhD; Ryan Swanson, BS; Umut Ulge, MD, PhD; Daniel Adriano Silva Manzano, PhD; Jonathan G. Drachman, MD; | Immune-stimulants and immune modulators | Antibody; Bispecifics; Checkpoint blockade; Costimulation; Cytokine; Inflammation; NK/NK T cell; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 577 | Poster Presentation | Engineered non-pathogenic synthetic biotic producing L-arginine synergize with PD-1-based cancer immunotherapy | Fernando P. Canale; Camilla Basso; Ning W. Li, PhD; Anna Sokolovska, PhD; Michela Perotti; Michael J. James, BS; Wenjie Jin; Jean-Philippe Theurillat; Daniel Leventhal; Kip A. West, PhD; Jose Lora; Federica Sallusto; Roger Geiger, PhD; | Immune-stimulants and immune modulators | Checkpoint blockade; Immune adjuvant; Immune suppression; Metabolism; Systems biology; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 578 | Poster Presentation | Tumor selective immune responses of STA551, a novel anti-CD137 agonist antibody activated by extracellular ATP | Yoshinori Narita, Ph.D.; Mika Kamata-Sakurai, PhD; | Immune-stimulants and immune modulators | Antibody; Checkpoint blockade; Costimulation; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 579 | Poster Presentation | Lactate Dehydrogenase C-associated molecular networks predict enhanced tumor growth and impaired immune response in breast cancer. | Julie Decock, PhD; Adviti N. Jana; Julie Decock, PhD; | Immune-stimulants and immune modulators | Carcinogenesis; Immune contexture; Immune suppression; Tumor antigens; Tumor evasion; Tumor microenvironment |
| 580 | Poster Presentation | High dose-rate brachytherapy of localized prostate cancer converts tumors from cold to hot | Simon P. Keam, PhD; Heloise Halse; ThuNgoc Nguyen; Minyu Wang; Nicolas Van Kooten Losio; Catherine Mitchell; Franco Caramia; David J. Byrne; Sue Haupt; Georgina Ryland; Phillip K. Darcy; Shahneen Sandhu, MBBS FRACP; Piers Blombery; Ygal Haupt; Scott G. Williams; Paul J. Neeson, PhD; | Immune-stimulants and immune modulators | Bioinformatics; Clinical study; Gene expression; Immune contexture; Immune suppression; Inflammation; Radiotherapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| 581 | Poster Presentation | Effects of Acoustic Immune Priming with Low-Intensity Focused Ultrasound (LOFU) and Trabectedin on a Murine Model of Osteosarcoma | Shannon Keisling; | Immune-stimulants and immune modulators | Immune tolerance; Radiotherapy; Solid tumors; Tumor antigens |
| 582 | Poster Presentation | Modulation of TCR repertoire by radiotherapy-activated NBTXR3 nanoparticles | Audrey Darmon, BS; Ping Zhang, PhD; Sebastien Paris, PhD; | Immune-stimulants and immune modulators | Radiotherapy; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs) |
| 583 | Poster Presentation | Novel, potent, and selective inhibitors of Hypoxia-Inducible Factor (HIF)-2α reverse pro-tumorigenic transcriptional programming in cancer, stromal, and immune cells | Kelsey E. Sivick Gauthier, PhD; Dana Piovesan, MSc; Kenneth V. Lawson; Soonweng Cho; Akshata R. Udyavar, Ph.D; Jean Chan; Ada Chen, BS; Jennie Au; Cesar Meleza; Xiaoning Zhao; Anh T. Tran; Samuel L. Drew; Balint Gal; Brandon R. Rosen, PhD; Manmohan R. Leleti, PhD; Elaine Ginn; Lixia Jin, PhD; Stephen W. Young; Jay P. Powers, PhD; Matthew J. Walters, PhD; | Immune-stimulants and immune modulators | Angiogenesis; Chemokine; Gene expression; Monocyte/Macrophage; Myeloid cells; Solid tumors; T cell; Targeted therapy; Tumor microenvironment |
| 584 | Poster Presentation | Therapeutic vascular normalization to promote tumor-associated tertiary lymphoid structures | Jessica Filderman, BS; Manoj Chelvanambi; Walter J. Storkus, PhD; | Immune-stimulants and immune modulators | Angiogenesis; Chemokine; Dendritic cell; Inflammation; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 585 | Poster Presentation | Intralesional injection of rose bengal improves the efficacy of gemcitabine chemotherapy against pancreatic cancer. | Patrick Innamarato, B.S.; Shari A. Pilon-Thomas, PhD; Jennifer Morse, MS; Sarah Asby; Amy Mackay; Matthew Beatty, PhD; Jaime Blauvelt; Scott Kidd; John E. Mullinax, MD; | Immune-stimulants and immune modulators | Chemotherapy; Inflammation; Solid tumors; T cell |
| 586 | Poster Presentation | Intratumoral DNA-based gene transfer as an efficient delivery approach to combine checkpoint-inhibiting antibodies with interleukin 12 | Liesl Jacobs, MPharm; Elien De Smidt; Nick Geukens, PhD; Kevin Hollevoet, PhD; Paul Declerck, PhD; | Immune-stimulants and immune modulators | Antibody; Checkpoint blockade; Costimulation; Cytokine; Gene expression |
| 587 | Oral Presentation | Tumor-activated Fc-engineered anti-CTLA-4 monoclonal antibody, XTX101, demonstrates tumor-selective PD and efficacy in preclinical models | Kurt Jenkins, PhD; Kurt Jenkins, PhD; Kurt Jenkins, PhD; Parker Johnson; Minjie Zhang; Wilson Guzman; Ugur Eskiocak, PhD; Megan McLaughlin; Caitlin O'Toole; Magali Pederzoli-Ribeil; Miso Park, PhD; John Williams, PhD; Margaret L. Karow, PhD; Jennifer O'Neil; Timothy Clackson; Ronan O'Hagan; | Immune-stimulants and immune modulators | Antibody; Checkpoint blockade; Immune toxicity; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 588 | Oral Presentation | Targeting GITR enhances human tumour-infiltrating T cell functionality in mismatch repair proficient primary colorectal carcinoma and liver metastases | Yannick S. Rakké, MD, MSc; Yannick S. Rakké, MD, MSc; Lucia Campos Carrascosa, PhD; Adriaan A. van Beek, PhD; Valeska de Ruiter, MSc; Michael Doukas, MD, PhD; Susan ter Borg, MD; Pascal G. Doornebosch, MD, PhD; Maarten Vermaas, MD, PhD; Erwin van der Harst, MD, PhD; Peter Paul LO. Coene, MD, PhD; Dirk J. Grünhagen, MD, PhD; Cornelis Verhoef, MD, PhD; Jan NM. IJzermans, MD, PhD; Dave Sprengers, MD, PhD; Jaap Kwekkeboom, PhD; | Immune-stimulants and immune modulators | Checkpoint blockade; Costimulation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 589 | Poster Presentation | Efficacy of oncolytic vaccinia virus requires infection of suppressive immune cells in the tumor microenvironment leading to their reprogramming and deletion | Kristin DePeaux, BS; Paolo DA. Vignali, BA; Saumendra Sarkar, PhD; Greg M. Delgoffe, PhD; | Immune-stimulants and immune modulators | Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 590 | Poster Presentation | Pre-conditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy | Christianne Groeneveldt, MSc; Priscilla Kinderman; Diana J.M. van den Wollenberg; Ruben L. van den Oever; Jim Middelburg; Dana A.M. Mustafa; Rob C. Hoeben; Sjoerd H. van der Burg, PhD; Thorbald van Hall, PhD; Nadine Van Montfoort; | Immune-stimulants and immune modulators | Antibody; Immune adjuvant; Inflammation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Bispecifics |
| 591 | Oral Presentation | Comparison of Two oHSV Vectors for the Treatment of Glioblastoma | Joseph Jackson, PhD; Joseph Jackson, PhD; Bonnie Hall, PhD; Lisa Bailey; E Chiocca, MD; Justus Cohen, PhD; Joseph C. Glorioso, III, PhD; | Immune-stimulants and immune modulators | Immune adjuvant; MDSC; Monocyte/Macrophage; Myeloid cells; Tumor microenvironment; Vaccine |
| 592 | Poster Presentation | Enhancing the therapeutic potential of oncolytic adenoviruses with vSENSᵀᴹ technology | Goo-Young Kim, Ph.D.; Ji Yeon Son; So Jin Lee; Sang Woo Jo; Changhoon In; Sang Hoon Kim; Joon Young Park; So-Young Kim; Gyu-Young Moon; Ji-Hye Choi; Suk-Hwan Kim; Minhyuk Yun; Hye Yeong Nam; Helen Cho; | Immune-stimulants and immune modulators | Immune contexture; Immune monitoring; Immune tolerance; Solid tumors; Systems biology; Targeted therapy; Tumor microenvironment |
| 593 | Poster Presentation | Tumoral Melanosis Mimicking Residual Melanoma After T-VEC Treatment | Song Y. Park, MD; Ata S. Moshiri, MD, MPH; Rouba Hadi, MD; Austin R. Green, MD; Jennifer Gardner, MD; Coley Doolittle-Amieva, PA-C; Song Y. Park, MD; | Immune-stimulants and immune modulators | Clinical study; Inflammation; Solid tumors; Tumor microenvironment; Vaccine |
| 594 | Poster Presentation | BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment | Monika Semmrich, PhD; Jean-Baptiste j. Marchand, PhD; Laetitia Fend, PhD; Matilda Rehn, PhD; Nathalie Silvestre, PhD; Linda Mårtensson, PhD; Johann Foloppe, PhD; Ingrid Teige, PhD; Eric Quéméneur, PhD; Björn Frendeus, PhD; | Immune-stimulants and immune modulators | Antibody; Checkpoint blockade; Immune suppression; Regulatory T cell (Treg cell); Solid tumors; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); Vaccine |
| 595 | Poster Presentation | Armed Myxoma virus demonstrates efficacy in syngeneic tumor models alone and in combination with immune checkpoint inhibitors | Lina S. Franco, PhD; Lino E. Torres-Dominguez, PhD; Joseph Mamola; Ana L. de Matos, PhD; Mario Abrantes; Benjamin S. Walker; Zachary Tacner; Cassandra Kien; Natalie M. Elliott; Grant McFadden, PhD; Leslie L. Sharp, PhD; | Immune-stimulants and immune modulators | Checkpoint blockade; Cytokine; Immune adjuvant; Myeloid cells; NK/NK T cell; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| 596 | Poster Presentation | Armed Myxoma virus demonstrates therapeutic activity in xenograft models | Lino E. Torres-Dominguez, PhD; Lina S. Franco, PhD; Mario Abrantes; Benjamin S. Walker; Zachary Tacner; Cassandra Kien; Natalie M. Elliott; Anna K. Waters; Grant McFadden, PhD; Steven J. Potts, PhD; Leslie L. Sharp, PhD; | Immune-stimulants and immune modulators | Checkpoint blockade; Costimulation; Gene expression; Immune adjuvant; NK/NK T cell; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 597 | Poster Presentation | In situ vaccination with oncolytic vesicular stomatitis virus improves anti-tumor immune response and outcome in bladder cancer | Coby Rangsitratkul, BSc; Christine Lawson, PhD; Lee-Hwa Tai, PhD; Lee-Hwa Tai, PhD; | Immune-stimulants and immune modulators | Immune suppression; MDSC; Solid tumors; Tumor evasion; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
| 598 | Oral Presentation | Reversal of epigenetic silencing of cGAS and STING in melanoma enhances the activity of tumor infiltrating lymphocytes | Rana Falahat, PhD; James Mulé, PhD; Anders E. Berglund, PhD; Patricio Perez- Villarroel; Ryan Putney, PhD; Shari A. Pilon-Thomas, PhD; Glen N. Barber, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; Bioinformatics; Chemokine; Epigenetics; Immune adjuvant; Tumor antigens; Tumor evasion; Tumor infiltrating lymphocytes (TILs) |
| 599 | Poster Presentation | New checkpoints controlling function of cytotoxic lymphocytes infiltrating human carcinoma | Anna S. Herbstritt, MS; Elfriede Noessner, Prof. Dr.; Petra U. Prinz, Dr.; Mani D. Kadiyala, BS; Melissa Maxwell, MS; Dingxue Yan, PhD; James Cardia, PhD; Simon P. Fricker, PhD; | Immune-stimulants and immune modulators | Adoptive immunotherapy; NK/NK T cell; RNA; Solid tumors; T cell; Tumor evasion |
| 600 | Poster Presentation | In Vitro Anticancer and Immunomodulatory Activities of NBT-167, a Dimer of Resveratrol | Jeffrey Zhang; Everett Henry; L. Harris Zhang; Wanying Zhang; | Immune-stimulants and immune modulators | Costimulation; Cytokine; NK/NK T cell; T cell |
| 601 | Poster Presentation | Development of improved small molecule STING agonists suitable for systemic administration | Maciej K. Rogacki; Stefan Chmielewski, PhD; Magdalena Zawadzka; Jolanta Mazurek; Katarzyna Wnuk-Lipinska; Kamil Kus; Karolina Gluza; Katarzyna Wójcik-Jaszczynska; Aleksandra Poczkaj; Lukasz Dudek; Wojciech Schonemann; Urszula Glowniak-Kwitek; Marcin Les; Marek Wronowski; Tushar Mahajan; Urszula Kulesza; David Synak; Karol Zuchowicz; Katarzyna Banaszak; Karolina Wiatrowska; Izabela Strojny; Miroslawa Gladysz; Justyna Jablonska; Ewelina Gabor-Worwa; Raghuram Tangirala; Luigi Stasi; Peter Littlewood; Krzysztof Brzózka; Monika Dobrzanska; | Immune-stimulants and immune modulators | Antigen presenting cells; Costimulation; Cytokine; Inflammation |
| 602 | Poster Presentation | STING Agonist-Based Treatment Promotes Vascular Normalization and Tertiary Lymphoid Structure Formation in the Therapeutic Melanoma Microenvironment | Manoj Chelvanambi, BS; Ronald Fecek, PhD; Jennifer L. Taylor, Ph.D.; Walter J. Storkus, PhD; | Immune-stimulants and immune modulators | Angiogenesis; Antigen presenting cells; Chemokine; Dendritic cell; Immune adjuvant; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 603 | Poster Presentation | Covalent attachment of a TLR7/8 agonist to tumor-targeting antibodies drives potent anti-tumor efficacy by synergistically activating FcgR- and TLR- signaling and enables safe systemic administration | Shelley E. Ackerman, PhD; Felix J. Hartmann, PhD; Cecelia I. Pearson, PhD; Joseph C. Gonzalez; Po Yi Ho; Samuel C. Kimmey; Andrew Luo; Benjamin Ackerman, PhD; Arthur Lee; Richard P. Laura, PhD; Jason C. Paik, MD, PhD; Karla A. Henning, PhD; David Y. Jackson, PhD; Steven J. Chapin, PhD; Bruce H. Devens, PhD; David Dornan, PhD; Sean C. Bendall, PhD; Edgar G. Engleman, MD; Michael N. Alonso, PhD; | Immune-stimulants and immune modulators | Antibody; Antigen presenting cells; Dendritic cell; Immune adjuvant; Monocyte/Macrophage; Myeloid cells; TLR; Tumor microenvironment |
| 604 | Poster Presentation | Intravenous CMP-001, a CpG-A Toll-like receptor 9 (TLR9) agonist delivered via a virus-like particle, causes tumor regression in syngeneic Hepa1-6 mouse models of hepatocellular carcinoma | Aaron J. Morris, PhD; Evan D. Walters; Bassel Akache; Michael J. McCluskie; Arthur M. Krieg, MD; | Immune-stimulants and immune modulators | Dendritic cell; TLR |
| 605 | Poster Presentation | Systemically administered HER2-targeted ISACs provoke a rapid, local response that engages the innate and adaptive arms of the immune system to eradicate tumors in preclinical models | Heidi N. LeBlanc; Cecelia I. Pearson, PhD; Justin A. Kenkel; LIsa Blum; Po Y. Ho; Angela Luo; Richard P. Laura, PhD; Matthew Zhou; Joshua Gregorio; Andrew Luo; Shelley E. Ackerman, PhD; Brian S. Safina; David Dornan, PhD; Michael N. Alonso, PhD; Marcin Kowanetz, Ph.D.; | Immune-stimulants and immune modulators | Antibody; Antigen presenting cells; Biomarkers; Cytokine; Gene expression; Monocyte/Macrophage; Myeloid cells; Solid tumors; TLR |
| 606 | Poster Presentation | Epidermal growth factor modulation of CXCL10 in keratinocytes and cutaneous cancers | Myles R. McCrary, PhD; David Gibbs, PhD; Carlos S. Moreno, PhD; Brian P. Pollack, MD/PhD; Myles R. McCrary, PhD; | Immune-stimulants and immune modulators | Carcinogenesis; Chemokine; Cytokine; Gene expression; Immune toxicity; Inflammation |
| 607 | Oral Presentation | TJ210 (MOR210), A Differentiated Anti-C5aR Antibody for Anti-Cancer Therapy | Jane Meng, PhD; Jane Meng, PhD; Zhengyi Wang, PhD; Wei Cao; Chan Chen; Joan Huaqiong Shen, MD, PhD; Christian Augsberger; Julia Neugebauer; Stefan Haertle; | Immune-stimulants and immune modulators | Antibody; MDSC; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| 608 | Poster Presentation | Immunodominant Listeria Epitopes Compete with Vaccine-Directed CD8+ T-cell Responses Rescued By Peptide-MHC Stabilizing Modifications | John C. Flickinger, Jr., BS; Jagmohan Singh, PhD; Yanki Yarman; Robert Carlson, BS; Scott A. Waldman, MD, PhD; Adam E. Snook, PhD; | Immune-stimulants and immune modulators | Immune adjuvant; Solid tumors; Tumor antigens; Vaccine |
| 610 | Poster Presentation | Technical challenges in monocyte-derived dendritic cell vaccine manufacturing; a QI project | Opal Reddy, MD; Sandhya Panch, MD; Chauha Pham; Mame Thioye Sall; Minh T. Tran, RN; Steven L. Highfill, PhD; Kamille A. West, MD; Ping Jin, PhD; Haksong Jin, PharmD, MSc; Malcolm K. Brenner, MD, PhD,FRCP,FRCPath; Jay A. Berzofsky, MD, PhD; David F. Stroncek, MD; Hoyoung M. Maeng, MD; | Immune-stimulants and immune modulators | Antigen presenting cells; Dendritic cell; Solid tumors; Targeted therapy; Tumor antigens; Vaccine |
| 611 | Poster Presentation | RNA-sequencing reveals a unique immune transcriptional landscape in the vaccine sites of patients with circulating T-cell responses to cancer immunization | Max O. Meneveau, MD; Pankaj Kumar, PhD; Kevin Lynch, MD; Karlyn E. Pollack, MD; Craig L. Slingluff, Jr., MD; Max O. Meneveau, MD; | Immune-stimulants and immune modulators | Antigen presenting cells; Dendritic cell; Immune adjuvant; Inflammation; T cell; TLR; Vaccine |
| 612 | Oral Presentation | Human CLEC9A antibodies deliver NY-ESO-1 antigen to CD141+ dendritic cells to activate naïve and memory NY-ESO-1-specific CD8+ T cells | Kelly-Anne Masterman; Oscar Haigh; Kirsteen Tullett; Ingrid Leal-Rojas; Carina Walpole; Frances Pearson; Jonathon Cebon; Christopher Schmidt; Liam O’Brien; Nikita Rosendahl; Ghazal Daraj; Irina Caminschi; Eric Gschweng; Roger Hollis; Donald Kohn; Mireille Lahoud; Kristen J. Radford, PhD; | Immune-stimulants and immune modulators | Antibody; Antigen presenting cells; Dendritic cell; Solid tumors; T cell; Tumor antigens; Vaccine |
| 841 | Poster Presentation | CRISPR Cas9 library screen in primary T cells and diffuse large B cell lymphoma cells to identify modulators in tumor-immune interaction | Qian Li; Zhengang Peng; | Immune-stimulants and immune modulators | Bispecifics; Immune toxicity; Leukemia/Lymphoma; Solid tumors; T cell lineages |
| 842 | Poster Presentation | A novel agonistic anti-CD40 targeting strategy with an affinity peptide binding feature for antigen cargo functionality: improving peptide stability and T cell proliferation | Ida R. Olsson; Mohamed Eltahir, MD; Sara M. Mangsbo, PhD MSc; | Immune-stimulants and immune modulators | Antibody; Antigen presenting cells; Checkpoint blockade |
| 843 | Poster Presentation | Reproducible, MoA-reflecting Reporter-based Bioassays to Enable Drug Development of Biosimilars and Biobetters | Jeffrey D. Nelson, PhD; Richard Moravec; Dun Li; Jennifer Wilkinson; Frank Fan, PhD; Mei Cong, PhD; | Immune-stimulants and immune modulators | Antibody; Autoimmunity; CAR T cells; Cytokine; Immune suppression; T cell; T cell lineages; Targeted therapy |
| 844 | Poster Presentation | Immunomodulatory Activity of Epigenetic Drugs Combinations in Mesothelioma: Laying the Ground for New Immunotherapeutic Strategies | Sara Cannito, Health biology; Ornella Cutaia; Carolina Fazio; Maria Fortunata Lofiego; Francesca Piazzini; Laura Solmonese; LUANA CALABRÒ; Michele Maio, MD; Alessia Covre, PhD; | Immune-stimulants and immune modulators | RNA; Post-translational modifications; Epigenetics; Biomarkers; Gene expression; Tumor antigens; Tumor microenvironment |
| 845 | Poster Presentation | Developing more potent inhibitors of vasoactive intestinal peptide signaling with enhanced efficacy in mouse models of leukemia | Sruthi Ravindranathan, PhD, MS; Jian-ming Li, PhD; Yiwen Li, MS; Passang Tenzin; Anish Majumdar; Edmund K. Waller, MD, PhD; | Immune-stimulants and immune modulators | T cell |
| 846 | Poster Presentation | Neospora caninum - an Immunotherapeutic Protozoan Against Solid Cancers | Louis Lantier, PhD; Agathe Poupee-Beauge, PhD; Céline DUCOURNAU; Anne Di Tommaso, PhD; Stéphanie Germon, PhD; Nathalie Moiré, PhD; Gordon Lee, MBChB; Antoine Touze, PhD; Isabelle Dimier-Poisson, PhD; | Immune-stimulants and immune modulators | Antibody; Cytokine; Immune adjuvant; Immune suppression; Neoantigens; Solid tumors; Tumor antigens; Tumor microenvironment; Tumor stroma; Vaccine |
| 847 | Poster Presentation | Inflammasome Activation in M2 Macrophage Restrain the Immune Suppressive Function | Ronghua Zhang, Ph.D; Tienan Wang, PhD; Qing Lin; | Immune-stimulants and immune modulators | Cytokine; Immune monitoring; Immune suppression; Inflammation; Monocyte/Macrophage; Myeloid cells; T cell; TLR |
| 848 | Poster Presentation | Prime-boost vaccination for the treatment of triple negative breast cancer | Seyedeh-Raheleh Niavarani; Christine Lawson, PhD; Lee-Hwa Tai, PhD; | Immune-stimulants and immune modulators | Biomarkers; Checkpoint blockade; Chemotherapy; Immune adjuvant; Surgery; T cell; Targeted therapy; Tumor infiltrating lymphocytes (TILs); TLR; Vaccine |
| 849 | Poster Presentation | Optimization of a GM3-containing liposomal vaccine that delivers antigen to CD169+ splenic macrophages | Maarten Nijen Twilhaar, Msc; Lucas Czentner Colomo; Joanna Grabowska; Alsya J. Affandi; Katarina Olesek; Hakan Kalay; Rene van Nostrum; Paul R. Crocker; Yvette van Kooyk; Gert Storm; Joke MM. den Haan; | Immune-stimulants and immune modulators | Antigen presenting cells; Monocyte/Macrophage; T cell; Targeted therapy; Vaccine |
| 850 | Poster Presentation | Immunological considerations for developing optimal whole tumor cell-derived cancer vaccines | Flavio Salazar Onfray, PhD; | Immune-stimulants and immune modulators | Clinical study; Dendritic cell; Immune adjuvant; Solid tumors; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Vaccine |
